Table 2 CD20-negative RD/PD after... | American Society of Hematology

Table 2

CD20-negative RD/PD after treatment with rituximab-containing combination chemotherapy

UPN	Age/sex	Diagnosis on admission	Status	Chemo Regimen	Total ritux	Duration until CD20⁻	Diagnosis (RD/PD)	Patho source	CD20 expression				Survival after CD20⁻
UPN	Age/sex	Diagnosis on admission	Status	Chemo Regimen	Total ritux	Duration until CD20⁻	Diagnosis (RD/PD)	Patho source	FCM	IHC	RT	CDS mutation	Survival after CD20⁻
1	65 / M	DLBCL	2 rel	R-salvage	8	2M	DLBCL	BM	−	−	N.A.	S97F[2/16]	6M†
2	37 / F	DLBCL	1 diag	R-CHOP	8	9M	DLBCL	BM	±*	±†	N.A.	V247I[2/10]	4M†
3	75 / M	DLBCL	1 diag	R-CHOP	7	10M	DLBCL	BM, CF	−	−	↓	WT	11M†
4	42 / M	FL G1	2 rel	R-CHOP	4	23M	DLBCL	BM	−	−	↓	WT	11M†
5	52 / M	FL G2	3 rel	R-cMOPP	14	81M	DLBCL	BM, LN‡	−	−	↓	WT	8M†

UPN	Age/sex	Diagnosis on admission	Status	Chemo Regimen	Total ritux	Duration until CD20⁻	Diagnosis (RD/PD)	Patho source	CD20 expression				Survival after CD20⁻
UPN	Age/sex	Diagnosis on admission	Status	Chemo Regimen	Total ritux	Duration until CD20⁻	Diagnosis (RD/PD)	Patho source	FCM	IHC	RT	CDS mutation	Survival after CD20⁻
1	65 / M	DLBCL	2 rel	R-salvage	8	2M	DLBCL	BM	−	−	N.A.	S97F[2/16]	6M†
2	37 / F	DLBCL	1 diag	R-CHOP	8	9M	DLBCL	BM	±*	±†	N.A.	V247I[2/10]	4M†
3	75 / M	DLBCL	1 diag	R-CHOP	7	10M	DLBCL	BM, CF	−	−	↓	WT	11M†
4	42 / M	FL G1	2 rel	R-CHOP	4	23M	DLBCL	BM	−	−	↓	WT	11M†
5	52 / M	FL G2	3 rel	R-cMOPP	14	81M	DLBCL	BM, LN‡	−	−	↓	WT	8M†

Status indicates disease status of those patients at the first treatment with rituximab; rel, relapse; duration until CD20−, duration (in months) until CD20− relapse or PD from the first rituximab treatment; total ritux, total times of rituximab treatment; patho source, sources of tumor tissues for pathologic analysis; BM, bone marrow; CF, cerebral fluid; LN, lymph node; RT, RT-PCR; N.A., not available; ↓, down-regulated; CDS, coding sequences; and survival after CD20−, duration from CD20-negative change until death.

19% of tumor cells were CD20⁺.

†

30% of tumor cells showed CD20⁺.

‡

Lymph node sample obtained at autopsy.

View Large

This Feature Is Available To Subscribers Only